Research Reports | Market Assessment
June 2016

Gram-Negative Infections | Current Treatment | US | 2016

Due to rising antibiotic resistance rates, powerful antibiotics historically reserved for later lines of therapy are becoming standard-of-care treatment for gram-negative infections (GNIs), particularly those acquired in healthcare facilities (e.g. hospitals, nursing homes, and long-term care facilities). Rising antimicrobial resistance rates have created an urgent need for new therapies with activity against multidrug-resistant gram-negative pathogens. As a result, commercial opportunities remain, particularly in the hospital setting, for emerging brands demonstrating clinical efficacy in patients with resistant infections, and especially those associated with high rates of mortality. Our Current Treatment content provides deep insights drawn from a survey of 100 hospital-based infectious diseases specialists, regarding how GNI inpatients are being treated in the United States today, and what factors are behind those treatment decisions.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports